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with hypoglycemia ED visits was in a declining trend of 2005-2009 and the lowest 
in 2009 (n=71,751). Consequently, the estimated annual expenditure of hospital 
admission from ED declined each year from 2005 ($2.90 billion) to 2009 ($1.25 
billion). The expenditure of hypoglycemia visits to ambulatory facilities 
fluctuated between 0.37 million in 2007 and 1.08 million in 2008, resulting in the 
estimated annual cost of approximately $80.46 million to $229.03 million, 
respectively. CONCLUSIONS: Annual direct medical cost associated with 
hypoglycemia in the U.S. was $3.49 billion in 2005 and declined to $1.84 billion in 
2009. The trend may be attributed to improvements in patient education, glucose 
monitoring, and new anti-diabetic medications with lower risk for hypoglycemia.  
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OBJECTIVES: To compare overall and diabetes-related health care utilization and 
expenditures in Medicare beneficiaries with diabetes prior to and after 
implementation of Part D. METHODS: Data were from the 2001-2010 Medical 
Expenditure Panel Survey. Medicare beneficiaries aged ≥65 years with self-
reported diabetes were identified, excluding individuals who were Medicare-
Medicaid dual eligible, had TRICARE, or other public coverage. The outcomes 
included overall and diabetes-related prescriptions, medical services utilization, 
and expenditures as well as out-of-pocket costs. These outcomes were analyzed 
using generalized linear model regression models with a log-link and gamma (for 
costs) or Poisson (utilization) distribution. All expenditures were inflated to 2010 
dollars. STATA survey commands were used to account for the complex survey 
design. RESULTS: There were 21,864 eligible Medicare beneficiaries with diabetes 
that comprised the sample population. After adjusting for sociodemographic 
characteristics and health status, implementation of Part D was associated with 
decreased out-of-pocket expenditures for insulin (Coeff.: -0.577, p<0.05) and oral 
antidiabetic agents (Coeff.:-1.292, p<0.001). No statistically significant effect on 
total health care and prescription expenditures were found. Implementation of 
Part D was associated with increased number of prescriptions filled (Coeff.: 0.145, 
p<0.001) without increase in emergency room visits or inpatient stays. 
CONCLUSIONS: The implementation of Medicare Part D increased medication 
use and reduced out-of-pocket costs for elderly diabetes patients. This reduction 
would allow for enhanced access to necessary medications, and thereby may 
have a positive impact on adherence and health outcomes.  
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OBJECTIVES: To determine the factors associated with prescription drug 
expenditure in patients with Diabetes Mellitus in the United States (US). 
METHODS: A retrospective cross-sectional study was conducted using the 2005-
2009 Medical Expenditure Panel Survey (MEPS) data, a nationally representative 
data on non-institutionalized US population. The study sample included diabetic 
patients identified using the diabetes diagnosis variable reported in the MEPS 
data and the ICD-9CM code: 250. Descriptive statistics were performed on the 
weighted sample to estimate the average prescription drug expenditure for 
patients with Diabetes. The Anderson Behavioral Model was used as the 
theoretical framework to identify factors associated with prescription drug 
expenditure and Ordinary Least Square regression was used for analysis. The 
prescription drug expenditure was log transformed to address skewed nature of 
cost data. RESULTS: An estimated 97 million patients were diagnosed with 
Diabetes Mellitus during 2005-2009. The average prescription drug expenditure 
for these patients was $3088 per year (95% CI: 2977-3199). The linear regression 
revealed that predisposing (age, race, marital status and employment status), 
enabling (region, health insurance coverage, prescription insurance coverage and 
usual source of care) and need (Charlson comorbidity index and general health 
status) characteristics were significantly associated with prescription drug 
expenditure. One year increase in age increased expenditure by 1.1%. Non-
Hispanic blacks had 33% higher expenditure than other races. Patients with 
health insurance coverage, prescription insurance coverage and usual source of 
care had 54%, 13% and 69% higher expenditure respectively as compared to 
those without these benefits. Charlson comorbidity index was positively 
associated with prescription drug expenditure. Patients with poor/fair self-
reported health status had 61% higher expenditure than other patients. 
CONCLUSIONS: Predisposing and enabling factors like race, employment, health 
and prescription insurance coverage and usual source of care had significant 
impact on prescription expenditure despite controlling for health status and 
need characteristics.  
 
PDB90  
ADHERENCE TO INSULIN THEAPY MAY SUBSTANTIALLY REDUCE COSTS 
ASSOCIATED WITH HEALTH RESOURCE UTILIZATION AMONG INSULIN PEN 
USERS WITH TYPE II DIABETES MELLITUS  
Chandran A1, Bonafede MM2, Saltiel-Berzin R1, Hirsch LJ1, Lahue BJ1 
1BD, Franklin Lakes, NJ, USA, 2Truven Health Analytics, Cambridge, MA, USA  
OBJECTIVES: To evaluate the impact of adherence to insulin therapy on health 
resource utilization (HRU) among patients with type 2 diabetes mellitus (T2DM) 
using an insulin pen. METHODS: The Truven Health MarketScan Research 
Database was used to identify patients with ≥1 one insulin pen claim between 
January 2006 and September 2010 with continuous enrollment for 12 months 
after that claim, had a diagnosis of T2DM and one prescription for an oral anti-
diabetic drug. Patient demographics, clinical characteristics, health care 
expenditures and medication (insulin pen) possession ratios (MPR) were also 
analyzed. Total costs were calculated by summing the patient and payer 
portions of all post-index health insurance claims. MPR was calculated using the 
days supply field of the insulin prescription claims, adjusted to account for 
variations in time between insulin refills. RESULTS: 32,361 patients met the 
study criteria. On average patients were 59.1 (SD=11.6) years old and 52.4% were 
male; 97.1% of the sample had capitated, non-capitated or a fee-for-service 
health plan (2.8% unknown). The baseline Charlson comorbidity score was 2.0 
(SD=1.7). The most common comorbidities included hypertension (46.7%), 
dyslipidemia (31.3%), ischemic heart disease (23.4%), diabetic neuropathy (19.6%), 
and renal disease (15.9%). Concomitant medication use was prevalent with at 
least one quarter of the sample filling a prescription for one or more of the 
following: sulfonylureas (27.1%), antidepressants (30.9%), biguanides (48.4%), 
antihyperlipidemics (77.8%) and antihypertensives (87.0%). All-cause 
expenditures for insulin pen users during the study period were $24,680 
(SD=$44,005). Average sample MPR was 0.63 (SD=0.29). When broken into 
quintiles there is a significant difference in health care expenditures between 
the least adherent (MPR 0-0.20, $26,310) and most adherent groups (MPR 0.81-
1.00, $23,839) (p=0.007). CONCLUSIONS: Managing patient adherence may 
present an opportunity to curb health resource utilization in T2DM insulin pen 
users.  
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OBJECTIVES: To examine the economic outcomes associated with dual-goal 
achievement of reaching glycated hemoglobin (HbA1c <7%) and low-density 
lipoprotein cholesterol (LDL-C <100mg/dL) targets in patients with type 2 
diabetes mellitus (T2DM). METHODS: Adult T2DM patients (ICD-9 codes: 250.x0, 
250.x2) were identified from the South Central Veterans Affairs Health Care 
Network (01/2004-06/2010) and followed until the end of data or death. A 
longitudinal design was adopted with patient information recorded in six-month 
cycles. Goal achievement status in each cycle was determined based on the 
average HbA1c and LDL-C levels using the area under the curve method. 
Economic outcomes included diabetes-related utilization events (inpatient (IP) 
days, number of outpatient (OP) visits) and diabetes-related medical service 
costs. The association between goal achievement status in a given study cycle 
and economic outcomes in the following cycle were assessed using multivariate 
generalized linear models, controlling for within-patient correlation. RESULTS: A 
majority of the 75,646 patients selected for the study were male (97.4%); average 
age was 64.7 years, mean BMI was 31.6 kg/m2, and median follow-up time was 
4.5 years. Compared with achievement of only the LDL-C goal, dual-goal 
achievement was associated with significantly fewer diabetes-related IP days 
(Incidence Rate Ratio (IRR): 0.93; 95% Confidence Interval (CI): 0.87-1.00), and OP 
visits (IRR: 0.88; CI: 0.87-0.89), and incurred significantly lower diabetes-related 
medical service costs (difference: -$130.89, p=0.02). Compared with achievement 
of only the HbA1c goal, dual-goal achievement was associated with significantly 
fewer OP visits (IRR: 0.98; CI: 0.97-1.00) but no statistical difference in the number 
of hospitalization days (IRR: 0.98, CI: 0.89-1.07) or diabetes-related medical 
service costs (difference:-$56.17, p=0.40). CONCLUSIONS: In this study of US 
Veterans with T2DM, dual-goal achievement was associated with fewer 
utilization events and lower costs when compared with only LDL-C goal 
achievement.  
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OBJECTIVES: The primary aim was to examine the economic outcomes 
associated with long-term adherence to oral diabetes medications in the 
Diabetes Mellitus (DM) population. The secondary aim was to examine the 
economic outcomes associated with having a history of an HbA1c test during the 
study period. METHODS: Patients continuously enrolled from January 01, 2006 to 
December 31, 2011 and did not have a diabetes diagnosis or medication one year 
prior to the index date were eligible for inclusion in this retrospective study 
(N=2090). Patients who had at least two oral diabetes medication fills in the 
index year, had an integrated medical and pharmacy benefit, and who did not 
have any injectable medications during the study period were stratified to 
examine the primary aim (N=781). Patients were defined as adherent if they had 
a medication possession ratio (MPR) of greater than 80% in all five years (N=153), 
the remainder were classified as non-adherent (N=628). To quantify the 
economic outcomes associated with a history of an HbA1c test, patients were 
stratified based on a history of HbA1c test. RESULTS: Compared to the non-
adherent group, the adherent group had lower unadjusted mean medical costs. 
The five-year total medical costs were $25,726 in the non-adherent group and 
$22,153 in the adherent group, a 16% difference (p≤0.05). A similar difference was 
observed when comparing inpatient and emergency room costs ($8694 vs. $5268, 
p≤0.001) Compared to patients without an HbA1C test during the study period 
(N=792), patients with an HbA1c test (N=1298) had lower total medical costs 
($36,599 vs. $29,153 respectively, p≤0.05) and inpatient and emergency room 
